North Immunology and Aethlon Medical have agreed to merge in an all-stock deal, with North Immunology leading the combined company focused on developing NOR-101, a bispecific antibody targeting inflammation in atopic dermatitis. The merger includes an oversubscribed $180 million private placement to fund operations through mid-2028. NOR-101's Phase 1a trial is set to start in early 2027, with further clinical data expected in 2027 and 2028. The combined company will trade on Nasdaq under the ticker NRTX, aiming to advance NOR-101 as a potential best-in-disease treatment for immune and inflammatory diseases.
The merger of Aethlon Medical and North Immunology is the story's subject, here is Pluang's market snapshot for context. Of 91 priced Health-sector US stocks tradable on Pluang, 59 rose and 27 fell today. Notable movers include ASND at USD 239.50 with a 1-day change of -3.31% and Pluang order activity of 91% Sell / 9% Buy, SANA at USD 3.00 with a 1-day change of +2.74% and Pluang order activity of 86% Sell / 14% Buy, and AMWL at USD 13.60 with a 1-day change of +2.03%. This data is as of Sep 17, 2026 17:02 WIB.
Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...
ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...
Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...
eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...
Balchem Corporation reported strong Q3 2026 results with net sales of $290.7 million, up 8.6% year-over-year, and net earnings of $46.7 million, a 16% increase. Growth was driven by all three segments: Human Nutrition and Health, Animal Nutrition and...
